Key result
Sirolimus cuts grade 3A or greater acute rejection ~43% vs. azathioprine after transplantation.
Why the study?
The effects of sirolimus on acute rejection and transplant vasculopathy in human heart transplant recipients were unknown.
Does sirolimus reduce acute rejection and prevent transplant vasculopathy in de novo heart transplant recipients compared to azathioprine?
RCT (n=136)
Open-label
2:1
Does sirolimus reduce acute rejection and prevent transplant vasculopathy in de novo heart transplant recipients compared to azathioprine?
Sirolimus significantly reduces acute rejection and prevents the progression of transplant vasculopathy at up to 2 years compared to azathioprine in de novo heart transplant recipients.
Answers are grounded in this paper and cite their sources.
Sirolimus may lower early rejection after transplantation; leaves open its role versus azathioprine pending randomized trials.
BACKGROUND: Sirolimus reduces acute rejection in renal transplant recipients and prevents vasculopathy in nonhuman primates and in-stent restenosis in humans. Its effects on rejection and transplant vasculopathy in human heart transplant recipients are unknown. METHODS AND RESULTS: In a randomized, open-label study, sirolimus was compared with azathioprine in combination with cyclosporine and steroids administered from the time of cardiac transplantation. We report 6-month rejection rates (primary end point), 12-month safety and efficacy data, and 6- and 24-month graft vasculopathy data in 136 cardiac allograft recipients randomly assigned (2:1) to sirolimus (n=92) or azathioprine (n=44). At 6 months, the proportion of patients with grade 3a or greater acute rejection was 32.4% for sirolimus 3 mg/d (P=0.027), 32.8% for sirolimus 5 mg/d (P=0.013), and 56.8% for azathioprine. Patient survival at 12 months was comparable among groups. Intracoronary ultrasound at 6 weeks, 6 months, and 2 years demonstrated highly significant progression of transplant vasculopathy in azathioprine-treated patients. At 6 months, a highly significant absence of progression in intimal plus medial proliferation and significant protection against luminal encroachment was evident in sirolimus-treated patients, and these effects were sustained at 2 years. CONCLUSIONS: Sirolimus use from the time of transplantation approximately halved the number of patients experiencing acute rejection. The measurable development of transplant vasculopathy at 6 months and 2 years in patients receiving azathioprine was not observed in patients receiving sirolimus.
No takes yet. Share an insight, caveat, or question.
Keogh et al. (2004) conducted an RCT in De novo heart transplant (n=136). Sirolimus vs. Azathioprine was evaluated on 6-month rejection rates (grade 3a or greater acute rejection) (p=0.027). Sirolimus use from the time of transplantation reduced the 6-month rate of grade 3a or greater acute rejection compared to azathioprine.
Synapse has enriched 10 related papers. Consider them for comparative context: